It is my pleasure to announce acceptance of another manuscript, third this year, for publication.
Title: Metallacarborane derivatives effective against Pseudomonas aeruginosa and Yersinia enterocolitica Authors: Wieslaw Swietnicki *, Waldemar Goldeman, Mateusz Psurski, Anna Nasulewicz-Goldeman, Anna Boguszewska-Czubara, Marek Drab, Jordan Sycz, Tomasz M. Goszczyński *
The manuscript has been accepted by the MDPI International Journal of Molecular Sciences on June 21st, 2021.
It is my pleasure to announce publication of the second manuscript this year. The work is a review describing use of secretory system components from bacterial pathogens in designing vaccines against bacterial pathogens. It is a long and detailed work showing published strategies and their effectiveness against Bacillus anthracis, Pseudomonas aeruginosa, Shigella flexneri, Yersinia pestis and many other pathogens. At the end, there is a summary and suggestions for designing better and longer-lasting vaccines.
The work has been published in MDPI Biomolecules under the Special Issue headed by myself.
A pioneer in scholarly open access publishing, MDPI (https://www.mdpi.com/) has supported academic communities since 1996. Based in Basel, Switzerland, MDPI has the mission to foster open scientific exchange in all forms, across all disciplines. Our over 300 diverse, peer-reviewed, open access journals are supported by over 80,000 academic editors. We serve scholars from around the world to ensure the latest research is freely available and all content is distributed under the Creative Commons Attribution License (CC BY).
Since 1996, MDPI has grown into a publishing house with more than 300 diverse open access journals, with further editorial offices in Beijing and Wuhan (China), Barcelona (Spain), Belgrade (Serbia), Manchester (UK) and Tokyo (JP) and freelance editors worldwide. In 2020 we opened an office in Poland for which we are looking for young graduates willing to stay connected to scientific research by helping researchers worldwide publish their latest results. This is also a great opportunity to start a first job in a dynamic multinational company which offers talented, enthusiastic and hard-working people interesting career development options.
You would start out as an Editorial Trainee, working in close collaboration with our Managing Editors, based in other countries, learning how to process papers properly from submission to publication. Once you have successfully completed your six-month traineeship you will be appointed as Assistant Editor. No previous editorial experience is required and you will be trained in this type of work.
You should share our passion for spreading the newly acquired knowledge of today’s scientific community and feel motivated to contribute to open access publishing.
Depending on your scientific background you will be assigned to work on journals related to your field. We are looking for Editors educated in all scientific fields.
Support the editorial process for academic research journals in your domain of expertise
Organize the peer-review process for submitted manuscripts and coordinate editorial decisions
Handle email communication between the parties involved in the publication process
Collaborate with other members of the editorial team and production team
· Master degree or PhD degree · Advanced knowledge of MS office applications (Word, Excel, PowerPoint) · Strong English skills in written and spoken language · Ability to multi-task, attention to detail · Experience with scholarly publishing would be beneficial · Poland residence permit
The mutated virus is becoming a problem for existing vaccines and therapeutics. Existing mRNA vaccines are based on short epitopes of viral proteins and have a severe limitation in preventing escape of mutant viruses from them. In the case of antibodies, they are made monoclonal and the problem is the same. Basically, the designs are becoming useless very soon after introduction. In the recent article by Wang et al in bioRxiv https://www.biorxiv.org/content/10.1101/2021.01.25.428137v2.full.pdf+html, the limitations were observed clearly for the South African variant SAdelta9 that was practically resistant to the Eli Lilly’s LY-CoV555 therapeutic antibody. The Moderna and Pfizer vaccines were also having problems with the new variants. Reconvalescent patients’ sera were about an order of magnitude less effective in neutralizing the mutated viruses.
In summary, the strategy of using short epitopes either in vaccines or monoclonal antibodies as the basis of vaccines/therapeutics has backfired. The result is not surprising as the strategy to have a successful therapeutic/vaccine has to be based on at least 3 targets. In this case, we have 1 target and 1 epitope.
We wish all researchers good luck in their efforts. The planners, however, should rethink the strategy to avoid chasing tails in the future.